Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06667726 · ClinicalTrials.gov registry record · Phase 2
An Investigational Scan (18F-DOPA PET/CT) for Improving the Clinical Management of Brain Tumors
A Phase 2 study, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 47
- Enrollment target
NCT06667726: Recruiting Phase 2 study, sponsored by Mayo Clinic.
NCT06667726 is a Phase 2 study that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 47 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06667726, a Phase 2 study, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 47 participants
- Enrollment target
Study Summary
This phase II trial studies how well the addition of 18F-DOPA (amino acid) positron emission tomography (PET)/computed tomography (CT) to standard of care (SOC) imaging can improve the clinical management of patients with brain tumors in over 50% of cases. PET is an imaging test that helps to measure the information about functions of tissues and organs within the body. A PET scan uses a radioactive drug (radiotracer) to show this activity. CT scan uses X-rays to create images of the bones and internal organs within the body. Combining a PET scan with a CT scan can help make the images easier to interpret. PET/CT scans are hybrid scanners that combine both of the two modalities into a single scan. This allows images of both anatomy (CT) and function (PET) to be taken during the same scan. The 18F-DOPA PET/CT scan is done with a very small amount of a radioactive tracer called FDOPA. The PET/CT scan is then used to detect the location of tumors. Using the 18FDOPA-PET/CT scan in addition to the SOC scan may improve the clinical management of patients with brain tumors.
Interventions
- PROCEDURE Computed Tomography
- PROCEDURE Positron Emission Tomography
- DRUG Fluorodopa F 18
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2026-03-24 |
| Est. Completion | 2028-05-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06667726
The ClinicalTrials.gov registry entry for NCT06667726 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Computed Tomography is the first listed.
NCT06667726 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06667726 about?
NCT06667726 is a clinical study titled "An Investigational Scan (18F-DOPA PET/CT) for Improving the Clinical Management of Brain Tumors". This phase II trial studies how well the addition of 18F-DOPA (amino acid) positron emission tomography (PET)/computed tomography (CT) to standard of care (SOC) imaging can improve the clinical management of patients with brain tumors in over 50% of cases. PET is an imaging test that helps to measur...
What is the current status of trial NCT06667726?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 2026-03-24. Estimated completion is 2028-05-31.
What interventions are being tested in trial NCT06667726?
The interventions under investigation include: Computed Tomography (PROCEDURE), Positron Emission Tomography (PROCEDURE), Fluorodopa F 18 (DRUG).
Who is sponsoring clinical trial NCT06667726?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.